CHRM1 and schizophrenia: A locus containing the DRD2 receptor, the only broadly validated target for treating schizophrenia, is also GWAS-significant, while neither was CHRM1, the other receptor agonist target of xanomeline nor were all other receptor loci except for 10 (Table 3).